Last $0.26 USD
Change Today -0.0075 / -2.80%
Volume 178.6K
AVXL On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

anavex life sciences corp (AVXL) Snapshot

Open
$0.26
Previous Close
$0.27
Day High
$0.26
Day Low
$0.25
52 Week High
08/15/13 - $0.80
52 Week Low
11/8/13 - $0.23
Market Cap
9.9M
Average Volume 10 Days
298.3K
EPS TTM
$-0.10
Shares Outstanding
38.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANAVEX LIFE SCIENCES CORP (AVXL)

Related News

No related news articles were found.

anavex life sciences corp (AVXL) Related Businessweek News

No Related Businessweek News Found

anavex life sciences corp (AVXL) Details

Anavex Life Sciences Corp., a pharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and various cancers. Its lead drug candidates include ANAVEX 2-73, which has completed Phase I single ascending dose clinical trial for the treatment of Alzheimer’s disease; and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept) for Alzheimer’s disease. The company’s product candidates also include ANAVEX 3-71, a drug candidate that is highly effective in very small doses against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037 for the treatment of prostate cancer. The company was founded in 2006 and is based in New York, New York.

1 Employees
Last Reported Date: 07/10/14
Founded in 2006

anavex life sciences corp (AVXL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2013.

anavex life sciences corp (AVXL) Key Developments

Anavex Life Sciences Corp. Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies

Anavex Life Sciences Corp. announced that it has secured cGMP manufacturing of ANAVEX 2-73 for its drug candidate trial supplies.

Anavex Secures cGMP Manufacturing for Drug Candidate Trial Supplies

Anavex Life Sciences Corp. announced that it has secured cGMP manufacturing of ANAVEX 2-73 for its drug candidate trial supplies.

Anavex Life Sciences Corp. Unveils Promising Preclinical Data for ANAVEX 3-71 in a Presentation at 2014 Alzheimer's Association International Conference

Anavex Life Sciences Corp. has unveiled promising preclinical data for ANAVEX 3-71 (formerly AF710B) in a presentation at the 2014 Alzheimer's Association International Conference (AAIC). The data shows ANAVEX 3-71 to be disease modifying and highly effective in very small doses at countering the effects of major Alzheimer's hallmarks in a transgenic mouse model 3xTg-AD. Those hallmarks include cognitive deficits, amyloid and tau pathologies, as well as neuroinflammation and mitochondrial dysfunctions. Reducing these major hallmarks has the potential to slow, stop or reverse Alzheimer's disease. ANAVEX 3-71 indicates extensive therapeutic advantages in Alzheimer's and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVXL:US $0.26 USD -0.0075

AVXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVXL.
View Industry Companies
 

Industry Analysis

AVXL

Industry Average

Valuation AVXL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANAVEX LIFE SCIENCES CORP, please visit www.anavex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.